We choose trastuzumab-based treatment for ERBB2 + breast cancer as an example of an oncogenic kinase-driven tumor where proteogenomic analyses and pharmacodynamic studies should provide significant insights into variability in treatment outcomes9,10. Here, ERBB2 is linked to breast carcinoma.